Shorted
Actinogen Medical logo
ACW
Pharmaceuticals, Biotechnology & Life Sciences

Actinogen Medical

Short interest
0.00%
0.00 pp 30d
as of 9 Oct 2026
Reported shorts
15.9K
Shares on issue
3.874B

Actinogen Medical (ACW) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
23 Sept

What could Actinogen Medical (ASX:ACW) mean for Healthcare Stocks?

Highlights Actinogen Medical has completed the underwriting of its remaining options, securing additional funding. The funding is expected to extend the company's cash runway into late twenty twenty-seven or early twenty twenty-eight. The company is progressing its Xanamem development programme as its pivotal Alzheimers trial moves towards results. Actinogen Medical Limited (ASX:ACW) has strengthened its funding position after completing the underwriting of its remaining options, providi...

Continue reading
Kalkine
Neutral
17 Sept

Why Is Actinogen Medical (ASX:ACW) Back in Focus After Today’s Update?

Highlights Actinogen Medical is in focus after fresh same-day trading activity among low-priced healthcare shares. The update keeps attention on clinical-stage healthcare development and the companys next operational steps. The broader Penny Stocks theme remains centred on execution, disclosure quality and strategic follow-through. Further company updates will help clarify how todays development fits into the longer operating pathway. Actinogen Medical (ASX:ACW) is drawing attention today aft...

Continue reading
Kalkine
Neutral
12 Aug

How Are Actinogen Medical (ASX:ACW), Alterity Therapeutics (ASX:ATH), Amplia Therapeutics (ASX:ATX) and Rhythm Biosciences (ASX:RHY) Responding to Sector Change?

Highlights Actinogen Medical and Alterity Therapeutics are being assessed through operational delivery, strategic priorities and the quality of their underlying platforms. Amplia Therapeutics and Rhythm Biosciences highlight how sector conditions can create different requirements across established and emerging business models. Capital discipline, customer relevance and consistent execution remain central as the four companies progress their current work programs. Australias market conversati...

Continue reading
Kalkine
Neutral
6 Aug

Actinogen (ASX:ACW): Can Cortisol Science & Trial Execution Change the Story?

Highlights Actinogen is in focus after it presented an updated cortisol rationale at a biotechnology summit in its latest update, creating a current test of evidence-led commercialisation. The Healthcare Stocks backdrop is shaped by clinical progress, regulatory pathways and channel expansion as Australia's market trades near record levels. The central operating question is cortisol science and trial execution, with trial milestones, approvals, sales traction and cash use forming the evidence-b...

Continue reading
Kalkine
Neutral
5 Aug

Actinogen Medical to Present Alzheimer's Treatment Insights in Clinical Trials Science Forum Webinar on 12 August 2026

Actinogen Medical (ASX:ACW) is set to host a live Clinical Trials Science Forum webinar on Wednesday, 12 August 2026 at 11am Sydney time, spotlighting the future of Alzheimer's treatment with expert neurologists and the company's senior leadership team. Key Points Webinar scheduled for Wednesday, 12 August 2026 at 11am Sydney time Chief Commercial Officer Andy Udell will moderate, following an introduction by CEO Dr Steven Gourlay Panel includes Dr Marwan Sabbagh, renowned neurologist and Alz...

Continue reading